Comparison of patients with ARDS
| Factor | No ARDS (n=108) | ARDS (n=21) | P value |
| Age, median (IQR) | 66 (58–72) | 61 (57–70) | 0.367 |
| Current smoking, n (%) | 17 (16.0%) | 8 (38.1%) | 0.033 |
| Histology, n (%) | |||
| Adenocarcinoma | 85 (80.2%) | 15 (78.9%) | 0.776 |
| Squamous cell carcinoma | 19 (17.9%) | 4 (21.1%) | |
| Benign | 2 (1.9%) | ||
| Hypertension, n (%) | 40 (38.8%) | 9 (50%) | 0.439 |
| Ischaemic heart disease, n (%) | 9 (8.7%) | 0 (0.0%) | 0.353 |
| Diabetes mellitus, n (%) | 9 (8.7%) | 4 (22.2%) | 0.103 |
| Lung disease, n (%) | 12 (11.7%) | 2 (11.1%) | 1.00 |
| Venous thromboembolic disease, n (%) | 11 (10.7%) | 0 (0.0%) | 0.367 |
| Weight (kg) median ARDS median (IQR) CDS mean (SD) | 75 (65–88) | 81 (62–93) | 0.485 |
| Height, median (IQR) | 173 (167–176) | 172 (169–176) | 0.915 |
| Haemoglobin, mean (SD) | 125 (16) | 120 (19) | 0.260 |
| Beta-blocker, n (%) | 17 (16.7%) | 3 (15.8%) | 1.00 |
| Dihydropyridine, n (%) | 9 (8.3%) | 6 (28.6%) | 0.0173 |
| Benzothiazepine, n (%) | 3 (2.78%) | 0 (0.0%) | 1.00 |
| Statin, n (%) | 28 (27.5%) | 5 (26.3%) | 1.00 |
| Aspirin, n (%) | 16 (15.7%) | 4 (21.1%) | 0.517 |
| ACE inhibitor or angiotensin II receptor antagonist | 20 (19.8%) | 4 (21.1%) | 1.00 |
| Regional anaesthesia, n (%) | 11 (10.9%) | 3 (15.8%) | 0.464 |
| Remifentanil, n (%) | 14 (14.7%) | 4 (22.2%) | 0.483 |
| Ketamine | 12 (12.5%) | 2 (11.1%) | 1.00 |
| Thoracoscopic approach, n (%) | 29 (29.0%) | 3 (16.7%) | 0.392 |
| Laparoscopic approach, n (%) | 84 (83.1%) | 17 (94.4%) | 0.302 |
ARDS, acute respiratory distress syndrome.